Treatment of human promyelocytic leukemia in the SCID mouse model with cotylenin A, an inducer of myelomonocytic differentiation of leukemia cells

Honma, Yoshio; Ishii, Yuki; Sassa, Takeshi; Asahi, Ken-ichi

doi:10.1016/s0145-2126(03)00071-7

Cited by 33 publications

(33 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Administration of cotylenin A significantly prolonged the survival of mice that had been inoculated with retinoidsensitive and -resistant NB4 cells, and no appreciable adverse effects were observed in the experiments (4).…”

Section: Introductionmentioning

confidence: 85%

“…Cells (1x10 4 per dish) were plated into 1.1 ml of a semisolid methylcellulose medium with 0.8% methylcellulose and 20% fetal bovine serum in triplicate for 14 days. A solution of 0.2 ml of PBS containing various concentrations of cotylenin A or vincristine was added to the semisolid medium.…”

Section: Methodsmentioning

confidence: 99%

“…We treated mice with cotylenin A at 5 mg/kg body weight, as described previously (4,6). This dose of cotylenin A was well-tolerated without a loss of body weight.…”

Section: Effects Of Cotylenin a And Vincristine On In Vivo Growth Of mentioning

confidence: 99%

See 2 more Smart Citations

Synergistic combination therapy with cotylenin A and vincristine in multiple myeloma models

Takahashi

Honma

Miyake

et al. 2015

International Journal of Oncology

Self Cite

View full text Add to dashboard Cite

Abstract. Multiple myeloma is a malignant proliferative disease of plasma cells in the bone marrow and remains largely incurable. Cotylenin A, a fusicoccane diterpene glycoside with a complex sugar moiety, was isolated as a plant-growth regulator. Cotylenin A has been shown to inhibit the growth of various cancer cells. Herein, we examined the anti-myeloma effects of cotylenin A using five human myeloma cell lines (RPMI-8226, KMS-11, KMS-26, KMS-12 PE and KMS-12 BM) and xenografts in immunodeficient mice. Cotylenin A and vincristine synergistically inhibited the growth and induced apoptosis in myeloma cells. While other microtubule-disturbing agents also showed co-operative effects with cotylenin A, other anticancer agents, such as doxorubicin, cisplatin, camptothecin, methotrexate, gemcitabine and 5-fluorouracil, did not show such co-operation with cotylenin A. These differences might be attributed to the effects on autophagic responses. Combined treatment with cotylenin A and vincristine induced autophagy (formation of LC3-II and degradation of p62 protein). However, doxorubicin did not enhance the autophagy induced by cotylenin A. A colony-forming assay indicated that the combined treatment with cotylenin A and vincristine more effectively suppressed the formation of large colonies, which have higher self-renewal activity than vincristine alone. Expression of pluripotency-associated transcription factor Sox2 mRNA in RPMI-8226 myeloma cells was significantly suppressed by treatment with cotylenin A. Combined treatment with cotylenin A and vincristine significantly inhibited the growth of KMS-26 myeloma cells as xenografts. Our results suggest that the combination of cotylenin A and vincristine may have therapeutic value. Recently, it was reported that cotylenin A modulates the 14-3-3 intracellular signaling pathway. The 14-3-3 proteins may be novel targets in treating myeloma.However, our study could not explain how the sensitization to vincristine is related to the effects of cotylenin A on the 14-3-3 signaling pathway and further studies will be needed.

show abstract

Section: Introductionmentioning

confidence: 85%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Synergistic combination therapy with cotylenin A and vincristine in multiple myeloma models

Takahashi

Honma

Miyake

et al. 2015

International Journal of Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…The diterpene glycoside cotylenin A induces differentiation in human acute myeloid leukaemia in both cell culture 2,3 and mouse models. 4 Additionally, the combination of cotylenin A either with rapamycin or interferon α resulted in arrest of tumor growth in breast carcinoma, 5 and tumor regression in non-small cell lung carcinoma, 6 as well as ovary carcinoma in mouse models. 7 Cotylenin A (Fig.…”

mentioning

confidence: 99%

A Structural Rationale for Selective Stabilization of Anti-tumor Interactions of 14-3-3 proteins by Cotylenin A

Ottmann

Weyand

Sassa

et al. 2009

Journal of Molecular Biology

Self Cite

View full text Add to dashboard Cite

“…1), 8) the sole fusicoccin-congener isolated as a potent plant-growth regulator from Cladosporium sp. 507W, 9,10) induced the differentiation of human acute myeloid leukemia cells 11) and apoptosis in human lung carcinoma cells in the presence of interferon-. 12) These useful biological activities of CN A toward mammalian y To whom correspondence should be addressed.…”

mentioning

confidence: 99%

Novel Fusicoccins R and S, and the Fusicoccin S Aglycon (Phomopsiol) fromPhomopsis amygdaliNiigata 2-A, and Their Seed Germination-stimulating Activity in the Presence of Abscisic Acid

Tajima

Nukina

Kato

et al. 2004

Bioscience, Biotechnology, and Biochemistry

Self Cite

View full text Add to dashboard Cite

Our search for new 3-hydroxyfusicoccins structurally related to cotylenin A from a culture of Phomopsis amygdali Niigata 2-A resulted in the isolation of novel 3-hydroxy fusicoccins, called fusicoccins R and S, and the fusicoccin S aglycon, called phomopsiol, together with known 3 -hydroxyfusicoccin J. The structure of phomopsiol was identified as that of O-demethyl-3-epicotylenol based on spectroscopic evidence. The structures of fusicoccins R and S were also determined to be those of 3 0 -deacetyl-3 -hydroxyfusicoccin A and 3 -hydroxy-3-epifusicoccin H. The lettuce seed germination-stimulating activity of fusicoccins R and S, phomopsiol and 3 -hydroxyfusicoccin J was examined in the presence of ABA; fusicoccin R and 3 -hydroxyfusicoccin J were highly active, while fusicoccin S and phomopsiol were inactive. The possible biosynthetic relationships among these novel fusicoccins having a 3 -or 3 -hydroxy group in their diterpene moiety are briefly discussed.

show abstract

Treatment of human promyelocytic leukemia in the SCID mouse model with cotylenin A, an inducer of myelomonocytic differentiation of leukemia cells

Cited by 33 publications

References 22 publications

Synergistic combination therapy with cotylenin A and vincristine in multiple myeloma models

Synergistic combination therapy with cotylenin A and vincristine in multiple myeloma models

A Structural Rationale for Selective Stabilization of Anti-tumor Interactions of 14-3-3 proteins by Cotylenin A

Novel Fusicoccins R and S, and the Fusicoccin S Aglycon (Phomopsiol) fromPhomopsis amygdaliNiigata 2-A, and Their Seed Germination-stimulating Activity in the Presence of Abscisic Acid

Contact Info

Product

Resources

About